Endometrial Cancer FIGO 2023 Stage (with molecular) — free guideline decision tool
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does Endometrial Cancer FIGO 2023 Stage (with molecular) do?
Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
How is the result calculated?
Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run Endometrial Cancer FIGO 2023 Stage (with molecular) now
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.